MYGN Aug 2022 32.000 call
| Previous Close | 2.4500 |
| Open | N/A |
| Bid | 0.5000 |
| Ask | 3.6000 |
| Strike | 32.00 |
| Expire Date | 2022-08-19 |
| Day's Range | 2.4500 - 2.4500 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 8 |
- GlobeNewswire
Myriad Genetics Showcases Advancements in Precision Medicine with Recent Oncology Portfolio Expansion and New Data Presentations at ASCO 2022
SALT LAKE CITY, May 26, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will present multiple studies at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the value of genetic insights to guide and clarify cancer treatment and risk assessment. The presentations underscore Myriad’s commitment to partnering with oncologists and other healthcare partners to support health equity and provide data-dri
- Zacks
Reasons to Hold on to Myriad Genetics (MYGN) Stock for Now
Investors are optimistic about Myriad Genetics (MYGN) owing to strong Q1 2022 results and growth in testing volumes.
- Zacks
Myriad Genetics (MYGN) Reports Loss in Q1, Gross Margin Down
Myriad Genetics' (MYGN) sales in the majority of the operating segments improved in the first quarter despite a challenging business environment.
